PHASQ PhaseBio (PNK) down 99% on 09 Mar 2026: what we watch next

PHASQ stock plunged 99.0% on 09 Mar 2026 to $0.000001, making PhaseBio Pharmaceuticals, Inc. (PHASQ) one of the top losers in U.S. markets during regular hours. We saw a tiny volume of 2,500 vs an average of 22,310, and the share closed far below its 50-day average of $0.000236 and 200-day average of $0.000666. This article explains the drivers behind the collapse, reviews cash and operating metrics, and gives Meyka AI’s grade and model forecast to frame risk and opportunity for traders and investors.

PHASQ stock: price action and trading metrics

Today PHASQ stock traded at $0.000001, down 99.0% from the previous close of $0.000100.

Volume was 2,500, well below the 30-day average of 22,310, highlighting extremely low liquidity and shallow order books on the PNK exchange in the United States.

Catalysts behind the decline and PHASQ news

PhaseBio’s history of Chapter 11 proceedings (filed October 23, 2022) and ongoing clinical and licensing uncertainty remain primary drivers of negative sentiment.

The company’s lead candidate bentracimab (PB2452) is still in development for ticagrelor reversal, but lack of clear commercialization news and thin trading pushed the stock lower as sellers cleared positions.

PHASQ stock financials and valuation metrics

Key reported metrics show EPS -2.14 and a pe ratio that is not meaningful for valuation given negative earnings and effectively zero market cap.

Price averages are weak with a 50-day average of $0.000236 and 200-day average of $0.000666, enterprise value listed negative, cash per share $1.421879 and operating cash flow per share -1.612914, which together indicate complex balance sheet dynamics tied to restructuring and accounting treatment.

Technicals, liquidity and sector context for PHASQ stock

PHASQ stock shows extreme volatility and low liquidity, with relative volume of 0.11 and daily price pinned at $0.000001 today.

The company sits in the Biotechnology industry within Healthcare, a sector that has broadly outperformed at times but that does not shield microcap issues like trading suspension risk, delisting threats, or restricted market maker support on PNK.

Meyka AI rates PHASQ with a score out of 100 and model forecast

Meyka AI rates PHASQ with a score of 62.88 out of 100 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month median of $0.000005 versus the current $0.000001, implying +400.00% potential upside. Forecasts are model-based projections and not guarantees.

Price targets, analyst coverage and PHASQ outlook

There is no published price target consensus and analyst coverage is effectively nil, leaving price discovery to thin market flows and any corporate or clinical updates.

We outline pragmatic scenarios: Bear $0.000001, Base $0.000005, Bull $0.000020 — these reflect extreme uncertainty and low liquidity rather than normalized biotech valuations.

Final Thoughts

PHASQ stock remains a top loser on 09 Mar 2026 after a steep one-day drop to $0.000001 on very low volume. The decline ties to legacy restructuring, uncertain commercial prospects for bentracimab, and minimal market-making support on the PNK exchange in the United States. Financial ratios show negative EPS -2.14 and operating cash flow pressure while reported cash per share appears material but must be interpreted within restructuring and share-count uncertainty. Meyka AI’s grade (Score 62.88, Grade B, Suggestion: HOLD) and model forecast median $0.000005 point to a speculative upside of +400.00%, but the path is high risk. Traders should treat PHASQ as a liquidity and event-driven play; we recommend watching corporate filings, clinical milestones, and any exchange notices. For real-time updates see the company site and social channels and our internal coverage page at Meyka for tick-by-tick context. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.